文献速递复苏、休克与脓毒症创伤与烧伤

SANGUINATE对延长性失血性休克模型全身及微循环变量的影响

Effects of Sanguinate on Systemic and Microcirculatory Variables in a Model of Prolonged Hemorrhagic Shock.
PubMed 文献 · Shock · 2019-01-01
一句话结论在大鼠延长性失血性休克模型中,SANGUINATE复苏较乳酸林格液和万汶显著延长生存时间、升高平均动脉压并改善组织氧分压。

研究在大鼠控制性分步失血45%并维持未治疗休克状态>60分钟后,分别以20%剂量单次推注SANGUINATE、乳酸林格液或万汶进行复苏,观察至死亡。SANGUINATE组生存时间显著长于万汶和乳酸林格液组,复苏后2小时组织氧分压显著升高而乳酸林格液和万汶组未升高,SANGUINATE组平均动脉压显著更高且虽低于基线但维持至死亡。作者认为,在延长性失血性休克后复苏,SANGUINATE较标准血浆扩容剂改善生存、平均动脉压和组织氧分压,此类临床前研究对确定新型复苏液在可能治疗时间范围内的疗效至关重要。

要点

  • 大鼠失血45%并休克>60分钟后,SANGUINATE组生存时间显著长于万汶组和乳酸林格液组。
  • 复苏后2小时SANGUINATE组组织氧分压显著升高,乳酸林格液组和万汶组未升高。
  • SANGUINATE组平均动脉压显著高于万汶和乳酸林格液组,虽低于基线但维持至死亡。
  • SANGUINATE为牛源聚乙二醇化羧基血红蛋白携氧载体,具有携氧、胶体渗透压及一氧化碳配体维持微血管灌注的特性。
  • 作者认为,鉴于失血性休克及全身缺血进行性加重,此类临床前研究对评估新型复苏液在可能治疗时间范围内的疗效至关重要。

适用人群与场景

  • 大鼠控制性分步失血模型,失血量45%体积,维持未治疗失血性休克状态>60分钟后进行复苏。

处置流程与药物剂量

  • 复苏采用20%剂量单次推注三种试验溶液之一:SANGUINATE、乳酸林格液或万汶(Hextend)。

研究设计与关键结果

  • 研究类型为动物实验(大鼠),比较SANGUINATE与乳酸林格液、万汶在超过「黄金一小时」后的复苏效果。
  • SANGUINATE组生存时间显著长于万汶组和乳酸林格液组。
  • 复苏后2小时SANGUINATE组组织氧分压(PISFO2)显著升高,乳酸林格液组和万汶组未升高。
  • SANGUINATE组平均动脉压显著高于万汶组和乳酸林格液组,虽低于基线但维持至死亡。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在延长性失血性休克后复苏,SANGUINATE较标准血浆扩容剂改善生存、平均动脉压和组织氧分压。
  • 作者认为,鉴于失血性休克及全身缺血进行性加重,此类临床前研究对确定新型复苏液在可能治疗时间范围内的疗效至关重要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Hemorrhage and its complications are the leading cause of preventable death from trauma in young adults, especially in remote locations. To address this, deliverable, shelf-stable resuscitants that provide therapeutic benefits throughout the time course of hemorrhagic shock and the progressive ischemic injury it produces are needed. SANGUINATE is a novel bovine PEGylated carboxyhemoglobin-based oxygen carrier, which has desirable oxygen-carrying and oncotic properties as well as a CO moiety to maintain microvascular perfusion.

OBJECTIVES: To compare the crystalloid (Lactated Ringer's Solution; LRS), and the colloid (Hextend) standards of care with SANGUINATE in a post "golden hour" resuscitation model.

METHODS: Rats underwent a controlled, stepwise blood withdrawal (45% by volume), were maintained in untreated hemorrhagic shock state for >60 min, resuscitated with a 20% bolus of one of the three test solutions, and observed till demise. Parameters of tissue oxygenation (PISFO2), arteriolar diameters, and mean arterial pressure (MAP) were collected.

RESULTS: SANGUINATE-treated animals survived significantly longer than those treated with Hextend and LRS. SANGUINATE also significantly increased tissue PISFO2 2 h after resuscitation, whereas LRS and Hextend did not. SANGUINATE also produced a significantly higher MAP, which was hypotensive compared to baseline, that endured until demise.

CONCLUSIONS: Resuscitation with SANGUINATE after prolonged hemorrhagic shock improves survival, MAP, and PISFO2 compared with standard of care plasma expanders. Since the pathologies of hemorrhagic shock and the associated systemic ischemia are progressive, preclinical studies of this nature are essential to determine efficacy of new resuscitants across the range of possible times to treatment.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Nugent WH, Cestero RF, Ward K, et al. Effects of Sanguinate on Systemic and Microcirculatory Variables in a Model of Prolonged Hemorrhagic Shock. Shock. 2019. PMID: 29252939. doi:10.1097/SHK.0000000000001082

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。